Integrated BioPharma, Inc. (OTCMKTS:INBP) Short Interest Up 600.0% in September

Integrated BioPharma, Inc. (OTCMKTS:INBPGet Free Report) saw a large increase in short interest in September. As of September 15th, there was short interest totalling 700 shares, an increase of 600.0% from the August 31st total of 100 shares. Based on an average daily volume of 45,200 shares, the short-interest ratio is presently 0.0 days.

Integrated BioPharma Price Performance

INBP remained flat at $0.25 during midday trading on Friday. The company has a market cap of $7.52 million, a P/E ratio of 24.99 and a beta of 0.66. The firm’s fifty day moving average is $0.21 and its 200 day moving average is $0.21. Integrated BioPharma has a 52-week low of $0.16 and a 52-week high of $0.30.

Integrated BioPharma (OTCMKTS:INBPGet Free Report) last released its earnings results on Friday, September 20th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $12.75 million for the quarter. Integrated BioPharma had a return on equity of 0.59% and a net margin of 0.22%.

Integrated BioPharma Company Profile

(Get Free Report)

Integrated BioPharma, Inc, together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.

Featured Articles

Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.